Rate of Adverse Effects for Dapagliflozin Similar to Placebo

This article originally appeared here.
Share this content:
Rate of Adverse Effects for Dapagliflozin Similar to Placebo
Rate of Adverse Effects for Dapagliflozin Similar to Placebo

MONDAY, Oct. 9, 2017 (HealthDay News) -- The overall incidence of adverse effects (AEs) and serious AEs (SAEs) is similar in patients with type 2 diabetes mellitus taking dapagliflozin or placebo, according to a study published online Sept. 26 in Diabetes, Obesity and Metabolism.

Serge Jabbour, M.D., from the Thomas Jefferson University in Philadelphia, and colleagues pooled data from 13 placebo-controlled trials of up to 24 weeks' duration (dapagliflozin: 2,360 patients; placebo: 2,295 patients).

The researchers found that over 24 weeks, the overall incidence of AEs and SAEs was similar between dapagliflozin and placebo (60.0 versus 55.7 percent and 5.1 versus 5.4 percent, respectively). The groups had similar rates of hypoglycemia, volume depletion AEs, urinary tract infections (UTIs), and fractures, while genital infections and renal function AEs were more frequent with dapagliflozin (5.5 versus 0.6 percent and 3.2 percent versus 1.8 percent, respectively). There were no cases of diabetic ketoacidosis (DKA) or ketonuria/metabolic acidosis, compared to one and three cases, respectively, with dapagliflozin.

"The overall incidence of AEs and SAEs was comparable in the dapagliflozin and placebo/control groups, including the incidence of hypoglycemia, volume depletion, fractures, UTIs, amputations, and DKA," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including AstraZeneca, which manufactures dapagliflozin and funded the study.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Enrollment Under the Affordable Care Act Down From Last Year

Enrollment Under the Affordable Care Act Down From ...

In most states, Saturday is the sign-up deadline for coverage beginning Jan. 1

Recalled Kotex Tampons Can Unravel Inside Body

Recalled Kotex Tampons Can Unravel Inside Body

Small number of reports include infections, vaginal irritation, localized vaginal injury

FDA: Some E-Cigarette Liquids Contain Erectile Dysfunction Meds

FDA: Some E-Cigarette Liquids Contain Erectile Dysfunction Meds

Sildenafil and tadalafil not approved to be sold over the counter and are being sold illegally

is free, fast, and customized just for you!




Already a member?

Sign In Now »